Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ICPA Security Details I may be close
Share Structure
Market Value1 $143,095 a/o Dec 09, 2011
Shares Outstanding 71,547,619 a/o Nov 14, 2011
ICPA READY TO FLY!!
We believe we haved stopped the downward trend and now has started to reverse itself IMO.
The trick is to buy the shares left out there, Most are in strong hands as like me as one of em, believe the others also are doing as I am,for me, I won't really sell any till we get to pennyland!!
Might sell a small amount to keep train going to the north.bought on friday ask to also get the price up,thats the key, and Others have said they won't sell any till it hits .05 or more!But also buying more next week!
There isn't very many shares left to grab!
I believe the non-serious investors are trapped and will help push this way undervalued stock up, the market price for company realalistic value is at (Market Cap (M )0.14)
.14 a share for 71 million o/s ,with alot of shares given to employees under lock and keys for years according to ICPA CEO!
According to one, says there is about 51 million for trading, Me and others think it is about 35 million available for trading! A bunch of us have about 25 million shares in our hands! look for ICPA under a couple boards such as penny stock millioniares and momo boards! My posting limit was reached today, so won't post those on this board till tomorrow!
Remember the shares are at .002 right now!,we need to force the price up also to get the non-serious investors and make em pay!
If you have or buy shares, like what we will do, sell in small batches, this thing could go on a long giganic ride if things go right! And ICPA is worth alot more than .14 that bloomberg have it at! Look at the other post and read ICPA board,don't let the q reports fool you,the company as a whole and new advertisers and revenues really just started this quarter and also shows such as static which will air in spring!
Jump in and buy at ask or higher and help get the non-serious investors and make a few dollars or a whole lot of dolars! This company is a gem ,goldmine, is way undervalued!
GO ICPA
zppb is there an I-hub brd?
I found some lower ones
PDGO.PK, My Baddies pick too.
http://stockcharts.com/h-sc/ui?s=PDGO&p=D&yr=0&mn=3&dy=0&id=p69040236907
52-Week High (Jan 13, 2011): 0.55
52-Week Low (Dec 9, 2011): 0.01
50-Day Moving Average: 0.03
200-Day Moving Average: 0.07
Share Statistics
Avg Vol (3 month): 284,453
Avg Vol (10 day)3: 862,000
Shares Outstanding: 61.13M
Float: 33.83M
$GSAG .051 on watch for possible move next week!!
ZPPB Security Details
Share Structure
Market Value1 Not Available
Shares Outstanding 18,000,000 a/o Sep 14, 2011
Float 250,000 a/o Nov 08, 2011
Authorized Shares 90,000,000 a/o Jun 30, 2011
AFFY reports FDA Advisory Committee voted in favor of Benefit/Risk Profile for Peginesatide for treatment of anemia in chronic kidney disease patients on dialysis (AFFY) 5.86 : Co and Takeda Pharmaceutical announce that FDA Oncologic Drugs Advisory Committee voted 15 to 1, with 1 abstention, that peginesatide demonstrated a favorable benefit/risk profile for use in the treatment of dialysis patients with anemia due to chronic kidney disease. While the FDA is not bound by the recommendations of its advisory committees, their guidance will be considered by the FDA in its review of the New Drug Application that was submitted for peginesatide in May 2011. The scheduled Prescription Drug User Fee Act date for peginesatide is March 27, 2012.
Our Products
Product Line
Pasta Sauce has all of the flavors of veal, pork and beef from the finest paste bases. We also pass our whole California Italian plum tomatoes through a finisher, which removes all of the seeds and skin giving the sauce a smooth silk texture. Tomatoes are the number one ingredient in our sauces and we do not weigh down our sauces with a large array of spices, herbs, paste or puree.
Princess Sauce is the perfect blend of our Pasta Sauce and Ultra Pasteurized heavy cream and the perfect amount of imported Pecorino Romano cheese and full 100% natural flavor. Unlike others, Bella's Princess Sauce is Alcohol Free and is not made with puree and dry milk power as are most pink vodka sauces.
Original Marinara is made from whole fresh California Italian roma tomatoes, course-ground in-house; fresh chopped garlic from Gilroy, California; and fresh Hawaiian basil for the sweetest marinara. Fresh basil is placed in the cooking kettle as well as large basil leaves added to each jar as they are filled with hot marinara during the packing process.
BTHR Bella Petrella's Holdings, Inc.
« Thread Started on Dec 4, 2011, 3:19pm » [Quote] [Modify] [Delete]
Bella Petrella’s Holdings, Inc., a Florida corporation, was formed to produce, manage and grow companies and products which are tomato based food products specifically formulated, cooked and blended to integrate in the pasta sauce and salsa retail grocery and institutional food markets. BPH’s products are all 100% all natural. During the cooking process, BPH removes most acidity that gives customers heartburn and acid reflux. To the Company’s knowledge BPH is the only company that takes this extra step providing customers with a relaxed, full flavored culinary experience without creating acid reflux as with most traditional tomato based products. Bella Petrellas Holdings, Inc is also a fully reporting public company trading under the symbol BTHR.
Apply to be an assistant I mean
Topic: BTHR Bella Petrella's Holdings, Inc. (Read 29 times)
Hot Christian Stocks
Administrator
*****
member is online
[email] [send pm]
Joined: Oct 2011
Posts: 21
Karma: 0
BTHR Bella Petrella's Holdings, Inc.
« Thread Started on Dec 4, 2011, 3:19pm » [Quote] [Modify] [Delete]
Bella Petrella’s Holdings, Inc., a Florida corporation, was formed to produce, manage and grow companies and products which are tomato based food products specifically formulated, cooked and blended to integrate in the pasta sauce and salsa retail grocery and institutional food markets. BPH’s products are all 100% all natural. During the cooking process, BPH removes most acidity that gives customers heartburn and acid reflux. To the Company’s knowledge BPH is the only company that takes this extra step providing customers with a relaxed, full flavored culinary experience without creating acid reflux as with most traditional tomato based products. Bella Petrellas Holdings, Inc is also a fully reporting public company trading under the symbol BTHR.
Our Products
Product Line
Pasta Sauce has all of the flavors of veal, pork and beef from the finest paste bases. We also pass our whole California Italian plum tomatoes through a finisher, which removes all of the seeds and skin giving the sauce a smooth silk texture. Tomatoes are the number one ingredient in our sauces and we do not weigh down our sauces with a large array of spices, herbs, paste or puree.
Princess Sauce is the perfect blend of our Pasta Sauce and Ultra Pasteurized heavy cream and the perfect amount of imported Pecorino Romano cheese and full 100% natural flavor. Unlike others, Bella's Princess Sauce is Alcohol Free and is not made with puree and dry milk power as are most pink vodka sauces.
Original Marinara is made from whole fresh California Italian roma tomatoes, course-ground in-house; fresh chopped garlic from Gilroy, California; and fresh Hawaiian basil for the sweetest marinara. Fresh basil is placed in the cooking kettle as well as large basil leaves added to each jar as they are filled with hot marinara during the packing process.
Spicy Marinara is a great marriage of fresh Hungarian Hot Peppers and fresh sweet imported Red Holland Peppers, with an elevated level of olive oil and our Original Marinara. Tossed with a seashell pasta, our Spicy Marinara has just the right level of heat without being overwhelming.
Sweet & Mild Salsa and Sweet & Spicy Salsa are delicious, non-traditional, fresh-tasting salsa like no other you've tasted! Hinted with just the right amount of sweet or sweet and spice and 100% natural.
http://bellapetrellasusa.com/Menu.html
BTHR Share Structure
Market Cap 10.22M
Outstanding 20.04M
Float 7.64M
Attachment: OTCQB.png (2.2 KB)
« Last Edit: Dec 4, 2011, 3:20pm by Hot Christian Stocks » Report to Mod - Link to Post - Back to Top IP: Logged
Read more: http://hotchristianstocks.proboards.com/index.cgi?board=hcsdailypicks&action=display&thread=160#ixzz1gAIf4XpP
STTH Security Details
Share Structure
Market Value1 $796,721 a/o Dec 02, 2011
Shares Outstanding 2,655,738 a/o Jun 30, 2011
Float 800,000 a/o Jun 30, 2011
Authorized Shares 5,000,000 a/o Jun 30, 2011
PBHG Security Details
Share Structure
Market Value1 $2,821,420 a/o Dec 02, 2011
Shares Outstanding 28,214,203 a/o Sep 30, 2011
Float 1,002,730 a/o Jul 15, 2011
Authorized Shares 750,000,000 a/o Sep 30, 201
DWIS Security Details :)
Share Structure
Market Value1 $2,058,397 a/o Dec 02, 2011
Shares Outstanding 34,306,620 a/o Jun 30, 2011
Float 2,040,000 a/o Jun 30, 2011
Authorized Shares 250,000,000 a/o Jun 30, 2011
MERG Security Details
Share Structure
Market Value1 $507,000 a/o Dec 02, 2011
Shares Outstanding 3,900,000 a/o Sep 30, 2011
Float Not Available
Authorized Shares 3,900,000 a/o Sep 30, 2011
Yes sir it is and it is one we need to get a group to hit it
GSRED 2mos? Now that's low!
UPZS Security Details
Share Structure
Market Value1 $6,949,267 a/o Dec 02, 2011
Shares Outstanding 63,175,152 a/o Sep 30, 2011
Float 93,600 a/o Sep 30, 2011
Authorized Shares 300,000,000 a/o Sep 30, 2011
Man I reall spotted a low one only 953k in th float we need to develop a team to hit it
I been watching PSRU
PSRU will be a $$$$$$$$$ maker today
BTHR will be a $$$$$$$$$$ maker
Looks Like SRWY will be a $$$$$$$$ Maker today
Nektar Therapeutics reports Affymax (AFFX) announced FDA Advisory Committee voted in favor of benefit/risk profile for peginesatide for treatment of anemia in chronic kidney disease patients on dialysis (NKTR) 5.10 : Nektar and Affymax have an exclusive agreement under which Nektar provides Affymax with its proprietary PEGylation technology for use in peginesatide. Under the terms of the agreement, Nektar receives manufacturing revenue, milestone and other payments, and is entitled to receive royalties on the global sales of peginesatide for all indications.
(OTCBB:GNTA.OB) today announced presentation of results from the Company's Phase 2b clinical trial using tesetaxel as initial, single-agent chemotherapy in women with advanced breast cancer. The trial is lead by Memorial Sloan-Kettering Cancer Center, New York, NY, in collaboration with three other U.S. based cancer centers. The data are being presented this week at the CTRC-AACR San Antonio Breast Cancer Symposium. Tesetaxel is the leading oral taxane in clinical development.
This ongoing study targets women who may be hormone-refractory, but previously untreated with chemotherapy for locally advanced or metastatic HER2-negative breast cancer. Prior adjuvant chemotherapy is allowed if the first relapse occurred at least 12 months after the last dose. To date, 33 patients have been accrued. More than 75% of patients had received adjuvant chemotherapy, and more than 50% of those chemotherapy regimens had included a standard injectable taxane. More than 50% had also received local radiotherapy. Approximately two-thirds of patients had progressed on one or more hormonal therapies.
Twenty-four patients are currently evaluable for response. Major objective responses (RECIST) have been observed in 50% of patients, including 1 complete response and 11 partial responses. Six of the 12 major responders have cleared more than 75% of their measurable disease. The disease control rate in this study, which includes major responders and patients with stable disease, is 83%.
Tesetaxel has been generally well-tolerated. The most common adverse effect (any grade) has been fatigue. Neutropenia has been the most common Grade 3-4 adverse event (52%); however, febrile neutropenia occurred in only 2 cases (6%). Consistent with prior studies, no hypersensitivity reactions were observed.
"These data confirm substantial activity for tesetaxel as initial chemotherapy for women with advanced, HER2-negative, breast cancer," said Dr. Loretta M. Itri, Genta's President, Pharmaceutical Development, and Chief Medical Officer. "Based on aggregate data from our multicenter Phase 2 trials, we will be conferring with FDA to identify potential registration strategies for tesetaxel in breast cancer."
Tesetaxel in Advanced Breast Cancer
In a prior Phase 2a, open-label, single arm, multicenter study, tesetaxel was evaluated as 2nd-line therapy in 2 patient cohorts with metastatic breast cancer who received starting doses of 27 mg/m2 or 35 mg/m2 administered once every 3 weeks. All patients had progressed on chemotherapy regimens that had included an anthracycline. Of 32 evaluable patients, 13 patients (38%) achieved a partial response and 11 patients achieved stable disease for a disease control rate of 75%. Neutropenia was the dose-limiting adverse effect. In the ongoing trial (described above) using tesetaxel as initial therapy for recurrent disease, the starting dose of 27 mg/m2 could be escalated in subsequent cycles to 35 mg/m2 as tolerated.
About Tesetaxel
Taxanes (including paclitaxel and docetaxel) are the most widely used chemotherapy drug class in cancer medicine. However, these agents are associated with serious safety issues, particularly hypersensitivity reactions related to intravenous infusions that are occasionally fatal and that require careful premedication and observation. Other prominent side-effects of this drug class include myelosuppression (low blood counts) and peripheral neuropathy (disabling nerve damage).
Unlike standard taxanes that must be administered intravenously, tesetaxel is a capsule that is taken by mouth. Compared with the standard agents, clinical and preclinical data show that tesetaxel:
Is active in diseases that are resistant to standard taxanes
Is not associated with serious (occasionally fatal) hypersensitivity reactions
Eliminates requirements for premedication (e.g., steroids, antihistamines, etc.)
Reduces damage to peripheral nerves
Offers flexible and convenient dosing for patients
Thus, tesetaxel offers substantial opportunities to improve patient convenience, safety, and anticancer activity.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company is developing tesetaxel, a novel, orally absorbed taxane that is in the same class of drugs as paclitaxel and docetaxel. As the leading oral taxane in clinical development, tesetaxel has been evaluated in a broad program of completed or ongoing Phase 2a/Phase 2b clinical trials. The Company has announced that gastric (stomach) cancer will be the lead indication for Phase 3 registration studies. Genta is exclusively marketing Ganite(R) (gallium nitrate injection) in the U.S, which is indicated for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The Company has developed proprietary oral formulations of the active ingredient in Ganite(R) that are being evaluated as potential treatments for diseases associated with accelerated bone loss. For more information about Genta, please visit our website at: www.genta.com.
AFFY reports FDA Advisory Committee voted in favor of Benefit/Risk Profile for Peginesatide for treatment of anemia in chronic kidney disease patients on dialysis (AFFY) 5.86 : Co and Takeda Pharmaceutical announce that FDA Oncologic Drugs Advisory Committee voted 15 to 1, with 1 abstention, that peginesatide demonstrated a favorable benefit/risk profile for use in the treatment of dialysis patients with anemia due to chronic kidney disease. While the FDA is not bound by the recommendations of its advisory committees, their guidance will be considered by the FDA in its review of the New Drug Application that was submitted for peginesatide in May 2011. The scheduled Prescription Drug User Fee Act date for peginesatide is March 27, 2012.
i like the pps of FLKI
FLKI is @ .045 it is scheduled for a 13 week promo no pimp and dump the company wannts sloe volume an PPS invrease over time
Kalo will pop / I have 220k share mysely, yestrdays volume showed frontloadin so beware it it gaps up I may go out, This has all indicationa of a pump and dump with posters showing no awareness disclaimers
DO NOT POST WHAT YOU THINK WILL MAKE MONEY, ONLY POST WHAT IS IN THE GREEN TODAY , WE WILL BE A MOMO BOARD
Followers
|
1
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
92
|
Created
|
12/07/11
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |